Saint Raphael

Researchers are evaluating the use of an AI-assisted method for the second reading of screening mammograms compared to the standard second reading by radiologists. This study aims to determine if the AI-assisted approach is not worse than the standard method and if it offers economic advantages. Participants are women undergoing mammograms as part of the breast cancer screening program in France. The study involves two reading pathways for mammograms eligible for a second reading: the conventional second reading by an accredited radiologist (control arm) and the AI-assisted second reading (experimental arm) using the MammoScreen device. In the AI-assisted arm, the AI first reviews the mammogram, and only if it flags suspicion does a radiologist perform a second review. The final decision uses the more concerning result from either arm to determine if recall for further examination is needed. Participants will undergo screening mammograms with both reading processes applied. Researchers will compare diagnostic performance and economic impact between the two pathways, focusing on recall rates at the end of a 24-month inclusion period. Women will participate according to the breast cancer screening schedule and provide informed consent for study involvement.

Post-thrombotic syndrome (PTS) is a frequent long-term complication of deep vein thrombosis (DVT) that significantly affects patients' quality of life and increases healthcare costs. This research aims to study how the extent of blood clot burden in the veins, measured by a special ultrasound score called the Venous Volumetric Index (VVI), can predict the likelihood and severity of PTS six months after a first episode of symptomatic DVT in the lower limbs. Understanding these predictive factors could help guide better treatment strategies for patients at risk of developing PTS. The study is a multicenter prospective cohort design involving patients diagnosed with a first episode of symptomatic lower limb DVT confirmed by ultrasound. Participants will be followed with clinical assessments and ultrasound scans at one week (only for those in biological research), one month, three months, and six months after diagnosis. Blood samples will be collected at baseline, one week, one month, and three months to examine inflammation and blood clotting factors. Quality of life questionnaires will be completed at three and six months. The VVI score will be calculated from ultrasound data to quantify the clot burden, and the Villalta scale will be used to assess PTS severity over the six-month follow-up period. During each visit, symptoms and clinical signs related to PTS will be evaluated, and color Doppler ultrasound of the lower limbs will be performed. Blood tests will help explore biological markers linked to PTS development. Patients will complete questionnaires about their quality of life to assess the impact of symptoms. The study concludes with the six-month visit, at which point researchers will analyze the association between initial clot burden and PTS outcomes. This comprehensive follow-up aims to improve the prediction and understanding of PTS after DVT.